AU2016240033B2 - 1-cyano-pyrrolidine compounds as USP30 inhibitors - Google Patents

1-cyano-pyrrolidine compounds as USP30 inhibitors Download PDF

Info

Publication number
AU2016240033B2
AU2016240033B2 AU2016240033A AU2016240033A AU2016240033B2 AU 2016240033 B2 AU2016240033 B2 AU 2016240033B2 AU 2016240033 A AU2016240033 A AU 2016240033A AU 2016240033 A AU2016240033 A AU 2016240033A AU 2016240033 B2 AU2016240033 B2 AU 2016240033B2
Authority
AU
Australia
Prior art keywords
cyanopyrrolidin
carboxamide
methyl
pyrazol
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016240033A
Other languages
English (en)
Other versions
AU2016240033A1 (en
Inventor
Karl Gibson
Alison Jones
Mark Kemp
Martin Stockley
Gavin Whitlock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mission Therapeutics Ltd
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1505429.9A external-priority patent/GB201505429D0/en
Priority claimed from GBGB1512829.1A external-priority patent/GB201512829D0/en
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Publication of AU2016240033A1 publication Critical patent/AU2016240033A1/en
Application granted granted Critical
Publication of AU2016240033B2 publication Critical patent/AU2016240033B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
AU2016240033A 2015-03-30 2016-03-24 1-cyano-pyrrolidine compounds as USP30 inhibitors Active AU2016240033B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1505429.9 2015-03-30
GBGB1505429.9A GB201505429D0 (en) 2015-03-30 2015-03-30 Novel compounds
GBGB1512829.1A GB201512829D0 (en) 2015-07-21 2015-07-21 Novel compounds
GB1512829.1 2015-07-21
PCT/GB2016/050851 WO2016156816A1 (en) 2015-03-30 2016-03-24 1-cyano-pyrrolidine compounds as usp30 inhibitors

Publications (2)

Publication Number Publication Date
AU2016240033A1 AU2016240033A1 (en) 2017-11-09
AU2016240033B2 true AU2016240033B2 (en) 2020-04-16

Family

ID=55646790

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016240033A Active AU2016240033B2 (en) 2015-03-30 2016-03-24 1-cyano-pyrrolidine compounds as USP30 inhibitors

Country Status (29)

Country Link
US (6) US10343992B2 (OSRAM)
EP (3) EP3943490A1 (OSRAM)
JP (3) JP6708661B2 (OSRAM)
KR (1) KR102578325B1 (OSRAM)
CN (2) CN107484415B (OSRAM)
AU (1) AU2016240033B2 (OSRAM)
BR (1) BR112017020900B1 (OSRAM)
CA (1) CA2976741C (OSRAM)
CO (1) CO2017011172A2 (OSRAM)
CY (1) CY1124170T1 (OSRAM)
DK (1) DK3277677T3 (OSRAM)
ES (1) ES2864950T3 (OSRAM)
HR (1) HRP20210791T2 (OSRAM)
HU (1) HUE054474T2 (OSRAM)
IL (1) IL254721B (OSRAM)
LT (1) LT3277677T (OSRAM)
MD (1) MD3277677T2 (OSRAM)
MX (1) MX373656B (OSRAM)
MY (1) MY188957A (OSRAM)
NZ (1) NZ736450A (OSRAM)
PL (1) PL3277677T3 (OSRAM)
PT (1) PT3277677T (OSRAM)
RS (1) RS61759B9 (OSRAM)
RU (1) RU2717238C2 (OSRAM)
SG (1) SG11201706542TA (OSRAM)
SI (1) SI3277677T1 (OSRAM)
SM (1) SMT202100287T1 (OSRAM)
WO (1) WO2016156816A1 (OSRAM)
ZA (1) ZA201705717B (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
CN107484415B (zh) * 2015-03-30 2021-01-29 特殊治疗有限公司 作为usp30抑制剂的1-氰基吡咯烷化合物
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) * 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) * 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
WO2017163078A1 (en) * 2016-03-24 2017-09-28 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as dbu inhibitors
CN109790112B (zh) 2016-09-27 2022-08-26 特殊治疗有限公司 具有作为usp30抑制剂活性的氰基吡咯烷衍生物
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
US10968172B2 (en) 2017-05-15 2021-04-06 Mitobridge, Inc. USP30 inhibitors
GB201708652D0 (en) * 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
JP7208931B2 (ja) * 2017-06-20 2023-01-19 ミッション セラピューティクス リミティド Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類
US11247987B2 (en) 2017-10-06 2022-02-15 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
ES2988920T3 (es) * 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
JP7434285B2 (ja) * 2018-08-14 2024-02-20 アムジエン・インコーポレーテツド Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用
MX2021002981A (es) * 2018-10-05 2021-05-14 Forma Therapeutics Inc Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).
CN120698985A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) * 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
WO2021202600A1 (en) * 2020-03-30 2021-10-07 The Scripps Research Institute Small molecule inhibitors of influenza hemagglutinin
CN111303128B (zh) * 2020-04-07 2020-10-27 苏州信诺维医药科技有限公司 一种多环类化合物、其制备方法及应用
BR112022020058A2 (pt) * 2020-04-08 2022-11-22 Mission Therapeutics Ltd N-cianopirrolidinas com atividade como inibidores de usp30
CN115667252A (zh) * 2020-05-28 2023-01-31 特殊治疗有限公司 用于治疗线粒体功能障碍的作为usp30抑制剂的n-(1-氰基-吡咯烷-3-基)-5-(3-(三氟甲基)苯基)噁唑-2-甲酰胺衍生物和对应噁二唑衍生物
BR112022019722A2 (pt) * 2020-06-04 2022-12-20 Mission Therapeutics Ltd N-cianopirrolidinas com atividade como inibidores de usp30
FI4161929T3 (fi) * 2020-06-08 2025-07-30 Mission Therapeutics Ltd 1-(5-(2-syaanipyridin-4-yyli)oksatsoli-2-karbonyyli)-4-metyyliheksahydropyrrolo[3,4-b]pyrroli-5(1h)-karbonitriili usp30-inhibiittorina käytettäväksi mitokondrioiden toimintahäiriön, syövän ja fibroosin hoitamisessa
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
WO2022140326A1 (en) * 2020-12-22 2022-06-30 Gilead Sciences, Inc. Substituted indole compounds
TWI861488B (zh) 2021-04-16 2024-11-11 美商基利科學股份有限公司 噻吩并吡咯化合物
KR20240056747A (ko) 2021-09-10 2024-04-30 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
AU2022362107A1 (en) * 2021-10-11 2024-05-02 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof
EP4441044A1 (en) 2021-12-01 2024-10-09 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
EP4604947A2 (en) * 2022-10-19 2025-08-27 Ohio State Innovation Foundation Compositions and methods for preventing cardiomyopathy
TW202446368A (zh) * 2023-02-28 2024-12-01 美商賽堤爾醫療公司 經取代之吡咯啶及吡咯啶酮化合物
CN119528901A (zh) * 2024-11-05 2025-02-28 上海市同济医院 噻唑类化合物、去sumo和/或去泛素化酶抑制剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077073A1 (en) * 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
WO2009129371A1 (en) * 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665754A (en) 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
WO2004022536A1 (en) 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2006091646A2 (en) * 2005-02-22 2006-08-31 The Regents Of The University Of Michigan Small molecule inhibitors of mdm2 and uses thereof
LT2303021T (lt) 2008-06-16 2019-06-25 University Of Tennessee Research Foundation Junginiai, skirti vėžio gydymui
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
MX2011004570A (es) 2008-10-31 2011-06-17 Merck Sharp & Dohme Antagonistas del receptor p2x3 para el tratamiento del dolor.
US8946231B2 (en) 2009-03-23 2015-02-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
JP5852658B2 (ja) * 2010-09-24 2016-02-03 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン デユビキチナーゼ阻害剤およびその使用方法
DK2780326T3 (en) * 2011-10-19 2019-03-04 Vivolux Ab PROCEDURE FOR INHIBITING DEUBIQUITINATION ACTIVITY
HK1208875A1 (en) 2012-01-12 2016-03-18 耶鲁大学 Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
TW201524952A (zh) 2013-03-15 2015-07-01 Araxes Pharma Llc Ｋｒａｓ ｇ１２ｃ之共價抑制劑
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016021629A1 (ja) 2014-08-06 2016-02-11 塩野義製薬株式会社 ＴｒｋＡ阻害活性を有する複素環および炭素環誘導体
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
CN107484415B (zh) * 2015-03-30 2021-01-29 特殊治疗有限公司 作为usp30抑制剂的1-氰基吡咯烷化合物
EP3322702B1 (en) 2015-07-14 2019-11-20 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) * 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
WO2017163078A1 (en) 2016-03-24 2017-09-28 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as dbu inhibitors
CN109790112B (zh) * 2016-09-27 2022-08-26 特殊治疗有限公司 具有作为usp30抑制剂活性的氰基吡咯烷衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077073A1 (en) * 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
WO2009129371A1 (en) * 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors

Also Published As

Publication number Publication date
DK3277677T3 (da) 2021-05-25
ES2864950T3 (es) 2021-10-14
WO2016156816A1 (en) 2016-10-06
RU2017134901A (ru) 2019-04-30
US10343992B2 (en) 2019-07-09
JP7389856B2 (ja) 2023-11-30
CY1124170T1 (el) 2022-05-27
CA2976741A1 (en) 2016-10-06
US11066365B2 (en) 2021-07-20
ES2864950T9 (es) 2021-11-18
MX373656B (es) 2020-04-02
ZA201705717B (en) 2019-09-25
JP2022123095A (ja) 2022-08-23
EP3277677B1 (en) 2021-02-24
US20180086708A1 (en) 2018-03-29
MY188957A (en) 2022-01-14
IL254721B (en) 2019-12-31
RU2717238C2 (ru) 2020-03-19
PL3277677T3 (pl) 2021-08-30
EP3277677B9 (en) 2021-07-14
US10689345B2 (en) 2020-06-23
LT3277677T (lt) 2021-05-25
CN112707893B (zh) 2023-10-31
RS61759B1 (sr) 2021-05-31
HUE054474T2 (hu) 2021-09-28
MD3277677T2 (ro) 2021-07-31
PT3277677T (pt) 2021-04-20
CN112707893A (zh) 2021-04-27
BR112017020900A2 (pt) 2018-07-10
NZ736450A (en) 2022-04-29
JP2020143124A (ja) 2020-09-10
SMT202100287T1 (it) 2021-07-12
EP3842427A1 (en) 2021-06-30
US20190322624A1 (en) 2019-10-24
CA2976741C (en) 2023-01-17
CO2017011172A2 (es) 2018-01-16
CN107484415A (zh) 2017-12-15
US20220251041A1 (en) 2022-08-11
HK1245266A1 (zh) 2018-08-24
EP3943490A1 (en) 2022-01-26
SI3277677T1 (sl) 2021-08-31
AU2016240033A1 (en) 2017-11-09
CN107484415B (zh) 2021-01-29
KR102578325B1 (ko) 2023-09-15
JP7216682B2 (ja) 2023-02-01
US11390584B2 (en) 2022-07-19
MX2017012566A (es) 2018-01-25
JP6708661B2 (ja) 2020-06-10
SG11201706542TA (en) 2017-10-30
KR20170131654A (ko) 2017-11-29
RU2017134901A3 (OSRAM) 2019-06-25
US20190284138A1 (en) 2019-09-19
EP3277677A1 (en) 2018-02-07
US20190270708A1 (en) 2019-09-05
US20200181086A1 (en) 2020-06-11
BR112017020900B1 (pt) 2023-02-23
IL254721A0 (en) 2017-11-30
HRP20210791T1 (hr) 2021-06-25
JP2018510183A (ja) 2018-04-12
US11053198B2 (en) 2021-07-06
RS61759B9 (sr) 2021-11-30
HRP20210791T2 (hr) 2021-12-10

Similar Documents

Publication Publication Date Title
US20220251041A1 (en) 1-cyano-pyrrolidine compounds as usp30 inhibitors
JP6959252B2 (ja) Ｄｕｂ阻害剤としての１−シアノピロリジン誘導体
AU2016373533B2 (en) Novel compounds
WO2017009650A1 (en) Cyanopyrrolidines as dub inhibitors for the treatment of cancer
EP3523291A1 (en) Cyano-substituted heterocycles with activity as inhibitors of usp30
ES2864948T3 (es) Aparato de colocación de remaches ciegos y dispositivo de procesamiento de remaches ciegos con un aparato de colocación de remaches ciegos
HK40043421A (en) 1-cyano-pyrrolidine compounds as usp30 inhibitors
HK40043421B (zh) 作为usp30抑制剂的1-氰基吡咯烷化合物
HK1245266B (zh) 作为usp30抑制剂的1-氰基吡咯烷化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)